Botulinum toxin A - Medytox

Drug Profile

Botulinum toxin A - Medytox

Alternative Names: Botulift; Cunox; KbtxA; Meditoxin; MT 10107; MT 10109; Neuronox; Siax

Latest Information Update: 26 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Medy-Tox
  • Developer Medytox
  • Class Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Muscle relaxants
  • Mechanism of Action Acetylcholine inhibitors; Membrane transport protein modulators; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Blepharospasm; Equinus foot deformity; Glabellar lines; Muscle spasticity; Spasm
  • Phase III Torticollis
  • Phase II Hypertrophy

Most Recent Events

  • 17 Jul 2017 Medy-Tox initiates enrolment in a phase III trial for Facial wrinkles in South Korea (NCT03317574)
  • 06 Jul 2017 Phase-III clinical trials in Torticollis in South Korea (Injection) (NCT03232320)
  • 04 Jul 2017 Medy-Tox completes a phase III trial for Blepharospasm (NCT03216473)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top